Drug Profile
Research programme: Nanobodies - Ablynx/Merck Serono
Alternative Names: ALX-0751Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Ablynx
- Developer Ablynx; Merck Serono
- Class Anti-inflammatories; Antineoplastics; Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Immunological disorders; Inflammation; Neurological disorders; Osteoarthritis
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Osteoarthritis in Belgium (Parenteral)
- 19 Jun 2018 Ablynx has been acquired by Sanofi
- 04 Nov 2017 No recent reports of development identified for research development in Neurological-disorders in Belgium (Parenteral)